Interview with CEO Sofia Heigis about the news that Oncopeptides opts to abandon Type II variation process for Pepaxti, and Price negotiations in Germany.
Read the press release and the Q&A for investors
Learn more about the company Oncopeptides and the work we do to redefine cancer care
Learn more about the company Oncopeptides and the work we do to redefine cancer care
Learn more about the company Oncopeptides and the work we do to redefine cancer care
Learn more about the company Oncopeptides and the work we do to redefine cancer care
